Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Completed · Phase 2

Conditions studied: Non-Small-Cell Lung Carcinoma

In brief

Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.

Key facts

Study ID

NCT00105092

Run by

Eli Lilly and Company

People needed

50

Starts

2005-03-01

Expected to finish

2007-02-01

Last updated by the study team

2007-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be at least 18 years old
• Must have been diagnosed with advanced or metastatic non-small cell lung cancer
• Must be able to visit the doctor's office every 28 days for 6 months or longer.

You may not qualify if…

• Pregnant or breastfeeding women
• Have other significant medical problems as determined by your physician
• Are unable to swallow tablets
• Have a history of significant heart disease

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. — Tampa, Florida, United States
• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. — Nashville, Tennessee, United States
• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.